TOVX Stock Summary and Trading Ideas (Theriva Biologics | AMEX:TOVX)

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.

Theriva Biologics trades on the AMEX stock market under the symbol TOVX.

As of July 24, 2026, TOVX stock price was flat at $0.22 with 85,520 million shares trading.

TOVX has a beta of 0.97, meaning it tends to be less sensitive to market movements. TOVX has a correlation of 0.02 to the broad based SPY ETF.

TOVX has a market cap of $10.10 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, TOVX traded as high as $17.50 and as low as $.16.

The top ETF exchange traded funds that TOVX belongs to (by Net Assets): VXF.

TOVX has underperformed the market in the last year with a price return of -56.7% while the SPY ETF gained +17.5%. TOVX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -42.3% and -6.2%, respectively, while the SPY returned +4.4% and -1.8%, respectively.

TOVX support price is $.21 and resistance is $.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TOVX shares will trade within this expected range on the day.